ANEB

Anebulo Pharmaceuticals (ANEB)

Anebulo Pharmaceuticals Inc

から:

Regulatory News

Text Search:

次の項目別のソート:

Non-Regulatory News

Showing the most relevant articles for your search:NASDAQ:ANEB

1 2 3 4 次へ >>

日付	受信時刻	ニュースソース	見出し	コード	企業名
2024/06/18	05 : 23	Edgar (US Regulatory)	Form 4 - Statement of changes in beneficial ownership of securities	NASDAQ:ANEB	Anebulo Pharmaceuticals Inc
2024/06/18	05 : 23	Edgar (US Regulatory)	Form 4 - Statement of changes in beneficial ownership of securities	NASDAQ:ANEB	Anebulo Pharmaceuticals Inc
2024/06/18	05 : 05	Edgar (US Regulatory)	Form 8-K - Current report	NASDAQ:ANEB	Anebulo Pharmaceuticals Inc
2024/05/16	05 : 31	Edgar (US Regulatory)	Form 10-Q - Quarterly report [Sections 13 or 15(d)]	NASDAQ:ANEB	Anebulo Pharmaceuticals Inc
2024/05/16	05 : 15	Edgar (US Regulatory)	Form 8-K - Current report	NASDAQ:ANEB	Anebulo Pharmaceuticals Inc
2024/05/16	02 : 05	Business Wire	Anebulo Pharmaceuticals Reports Third Quarter Fiscal Year 2024 Financial Results and Recent Updates	NASDAQ:ANEB	Anebulo Pharmaceuticals Inc
2024/02/14	06 : 30	Edgar (US Regulatory)	Form 10-Q - Quarterly report [Sections 13 or 15(d)]	NASDAQ:ANEB	Anebulo Pharmaceuticals Inc
2024/02/14	06 : 15	Edgar (US Regulatory)	Form 8-K - Current report	NASDAQ:ANEB	Anebulo Pharmaceuticals Inc
2024/02/14	06 : 05	Business Wire	Anebulo Pharmaceuticals Reports Second Quarter Fiscal Year 2024 Financial Results and Recent Updates	NASDAQ:ANEB	Anebulo Pharmaceuticals Inc
2023/11/22	06 : 01	Edgar (US Regulatory)	Form 8-K - Current report	NASDAQ:ANEB	Anebulo Pharmaceuticals Inc
2023/11/15	06 : 05	Business Wire	Anebulo Pharmaceuticals Reports First Quarter Fiscal Year 2024 Financial Results and Recent Updates	NASDAQ:ANEB	Anebulo Pharmaceuticals Inc
2023/10/30	22 : 31	Edgar (US Regulatory)	Form ARS - Annual Report to Security Holders	NASDAQ:ANEB	Anebulo Pharmaceuticals Inc
2023/10/30	22 : 22	Edgar (US Regulatory)	Form DEF 14A - Other definitive proxy statements	NASDAQ:ANEB	Anebulo Pharmaceuticals Inc
2023/10/20	06 : 18	Edgar (US Regulatory)	Form PRE 14A - Other preliminary proxy statements	NASDAQ:ANEB	Anebulo Pharmaceuticals Inc
2023/10/07	05 : 10	Edgar (US Regulatory)	Form 8-K - Current report	NASDAQ:ANEB	Anebulo Pharmaceuticals Inc
2023/10/07	05 : 06	Business Wire	Anebulo Pharmaceuticals Announces New CEO	NASDAQ:ANEB	Anebulo Pharmaceuticals Inc
2023/10/07	05 : 06	Business Wire	Anebulo Pharmaceuticals Announces Appointment of Bimal Shah to its Board of Directors	NASDAQ:ANEB	Anebulo Pharmaceuticals Inc
2023/10/03	06 : 01	Edgar (US Regulatory)	Form 3 - Initial statement of beneficial ownership of securities	NASDAQ:ANEB	Anebulo Pharmaceuticals Inc
2023/09/23	05 : 05	Edgar (US Regulatory)	Form 10-K - Annual report [Section 13 and 15(d), not S-K Item 405]	NASDAQ:ANEB	Anebulo Pharmaceuticals Inc
2023/09/21	05 : 29	Business Wire	Anebulo Pharmaceuticals Reports Fourth Quarter and Fiscal Year 2023 Financial Results and Recent Updates	NASDAQ:ANEB	Anebulo Pharmaceuticals Inc
2023/09/21	05 : 15	Edgar (US Regulatory)	Form 8-K - Current report	NASDAQ:ANEB	Anebulo Pharmaceuticals Inc
2023/09/05	21 : 00	Edgar (US Regulatory)	Form 8-K - Current report	NASDAQ:ANEB	Anebulo Pharmaceuticals Inc
2023/08/30	21 : 00	Business Wire	Anebulo Pharmaceuticals to Present at Upcoming Investor and Scientific Conferences	NASDAQ:ANEB	Anebulo Pharmaceuticals Inc
2023/08/21	21 : 00	Business Wire	Anebulo Receives Positive Feedback from FDA on Path to Advance Phase 3 Clinical Development of ANEB-001 and Completes Dosing of Phase 2 Extension	NASDAQ:ANEB	Anebulo Pharmaceuticals Inc
2023/05/12	05 : 07	Edgar (US Regulatory)	Quarterly Report (10-q)	NASDAQ:ANEB	Anebulo Pharmaceuticals Inc
2023/05/11	21 : 16	Edgar (US Regulatory)	Current Report Filing (8-k)	NASDAQ:ANEB	Anebulo Pharmaceuticals Inc
2023/05/11	21 : 00	PR Newswire (US)	Anebulo Pharmaceuticals Reports Third Quarter Fiscal 2023 Financial Results and Recent Updates	NASDAQ:ANEB	Anebulo Pharmaceuticals Inc
2023/04/05	07 : 33	Edgar (US Regulatory)	Initial Statement of Beneficial Ownership (3)	NASDAQ:ANEB	Anebulo Pharmaceuticals Inc
2023/03/28	21 : 02	Edgar (US Regulatory)	Current Report Filing (8-k)	NASDAQ:ANEB	Anebulo Pharmaceuticals Inc
2023/03/28	21 : 00	PR Newswire (US)	Anebulo Pharmaceuticals Announces Positive Complete Phase 2 Clinical Data Demonstrating Potential of ANEB-001 as a Treatment for Acute Cannabinoid Intoxication	NASDAQ:ANEB	Anebulo Pharmaceuticals Inc